H

    Harmony Biosciences Holdings (HRMY)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $39.38
    +0.17 (+0.43%)

    Market Cap: $2.29B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    71%(17/24)
    Avg Surprise
    +221.74%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$1.47
    Range$1.41 - $1.53
    2 analysts
    EPS Revisions
    3
    0
    7d
    3
    0
    30d
    EPS Estimate Drift
    90d ago$1.29-11.9%
    60d ago$1.22-16.6%
    30d ago$1.22-16.6%
    7d ago$1.22-16.6%
    Current$1.47
    Revenue Consensus
    $275M
    Range$270M - $279M
    11 analysts
    Period ending Dec 31, 2026
    EPS Consensus$1.67
    Range$1.58 - $1.76
    2 analysts
    Revenue Consensus
    $286M
    Range$274M - $295M
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$1.67---
    Sep 26EST
    		-$1.47---
    Jun 26
    Reported Aug 4
    		$1.28$0.97+31.96%Beat+39.1%
    Mar 26
    Reported May 7
    		$0.79$0.93-15.05%Miss+1.5%
    Dec 25
    Reported Feb 24
    		$0.57$0.86-33.72%Miss-47.2%
    Sep 25
    Reported Nov 4
    		$1.08$0.86+25.58%Beat+4.9%
    Jun 25
    Reported Aug 5
    		$0.92$0.96-4.17%Miss-12.4%
    Mar 25
    Reported May 6
    		$0.78$0.91-14.79%Miss-11.5%
    Dec 24
    Reported Feb 25
    		$1.08$0.82+31.71%Beat+140.0%
    Sep 24
    Reported Oct 29
    		$1.03$0.88+17.05%Beat+6.2%
    Jun 24
    Reported Aug 6
    		$1.05$0.12+775.00%Beat+38.2%
    Mar 24
    Reported Apr 30
    		$0.88$0.69+27.54%Beat+33.3%
    Dec 23
    Reported Feb 22
    		$0.45$0.48-6.25%Miss-43.0%
    Sep 23
    Reported Oct 31
    		$0.97$0.81+19.75%Beat+2.1%
    Jun 23
    Reported Aug 1
    		$0.76$0.74+2.70%Beat+33.3%
    Mar 23
    Reported May 2
    		$0.66$0.56+17.86%Beat+29.4%
    Dec 22
    Reported Feb 21
    		$0.79$0.58+36.21%Beat+107.9%
    Sep 22
    Reported Nov 1
    		$0.95$0.19+400.00%Beat+658.8%
    Jun 22
    Reported Aug 2
    		$0.57$0.63-9.52%Miss+137.5%
    Mar 22
    Reported May 3
    		$0.51$0.42+21.43%Beat+34.2%
    Dec 21
    Reported Feb 28
    		$0.38$0.36+5.56%Beat+52.0%
    Sep 21
    Reported Nov 9
    		$-0.17N/A-132.69%Miss-21.4%
    Jun 21
    Reported Aug 10
    		$0.24$0.17+41.18%Beat+108.2%
    Mar 21
    Reported May 11
    		$0.38$-0.01+3900.00%Beat-
    Dec 20
    Reported Mar 25
    		$0.25$0.09+177.78%Beat-
    Sep 20
    Reported Nov 12
    		$-0.14$-0.15+6.67%Beat-
    Jun 20
    Reported Aug 19
    		$-2.93N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio10.59EV/EBITDA6.45x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin18.90%Operating Margin34.20%
    ROE20.50%ROIC15.01%
    Financial Health
    Debt/Equity0.15xInterest Coverage17.09x
    Current Ratio3.48xQuick Ratio3.45x
    Trading Statistics
    Beta0.91Avg Volume717.79K
    52-Week High$40.8752-Week Low$25.52

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$39.05
    SMA 20$38.89
    SMA 50$36.92
    SMA 200$34.07
    EMA 10$39.07
    EMA 20$38.53
    EMA 50$36.93
    EMA 200$34.17

    MACD

    Line: 0.78Signal: 0.82Hist: -0.04

    ADX

    ADX: 30.0+DI: 24.7-DI: 12.9

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down20.0
    PSAR$37.66

    Bollinger Bands

    Upper Band$40.15
    Lower Band$37.63
    %B Position648%(Upper)
    Band Width0.69

    RSI (14-Day)

    Neutral
    57.7

    Momentum Oscillators

    Stoch %K66.4
    Stoch %D68.3
    Williams %R-37.1
    ROC (10d)3.3%
    Momentum1.24
    CCI (20d)75.4
    MFI (14d)52.0

    Volatility Measures

    ATR (14d)$1.23(3.1%)
    StdDev (20d)0.63
    Hist Vol42.5%(High)

    Volume Flow

    VWAP$39.37
    OBV2.3M
    AD Line17.5M
    CMF (20d)0.103

    Volume Metrics

    Avg Vol (20d)709.5K
    Vol Ratio0.8x
    VWMA (20d)$38.86

    Pivot Points

    R3$40.12
    R2$39.90
    R1$39.56
    Pivot Point$39.34
    S1$39.00
    S2$38.78
    S3$38.44

    Advanced Oscillators

    TSI16.16
    Ultimate Osc51.7
    KST74.01

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$261.28M$215.39M$243.78M$239.46M$200.49M$184.73M$201.27M$186.04M$172.81M$154.62M$168.41M$160.27M
    Cost of Revenue$63.20M$44.51M$68.55M$59.65M$38.15M$31.99M$54.41M$42.78M$32.14M$27.48M$43.15M$32.30M
    Gross Profit$198.08M$170.88M$175.23M$179.81M$162.34M$152.74M$146.86M$143.26M$140.67M$127.13M$125.26M$127.97M
    Operating Expenses$108.77M$133.58M$136.67M$114.32M$114.16M$96.49M$91.13M$81.55M$119.31M$75.10M$85.06M$63.46M
    R&D$46.60M$69.38M$49.93M$54.96M$50.16M$34.54M$34.67M$25.39M$63.58M$22.19M$30.31M$17.50M
    SG&A$28.05M$32.51M$57.56M$29.81M$33.92M$31.24M$28.86M$28.59M$27.22M$25.68M$27.87M$22.55M
    Operating Income$89.32M$37.29M$38.56M$65.49M$48.18M$56.24M$55.73M$61.71M$21.36M$52.03M$40.20M$64.51M
    Interest Income$7.07M$5.76M$5.85M$5.73M$5.30M$5.04M$4.48M$4.93M$4.71M$4.43M$4.10M$4.11M
    Interest Expense$3.07M$3.23M$3.55M$3.62M$3.65M$3.84M$4.21M$4.35M$4.40M$4.54M$4.80M$16.78M
    Income Before Tax$93.27M$39.69M$40.76M$67.49M$49.64M$57.18M$56.16M$62.17M$21.69M$51.78M$39.69M$51.83M
    Income Tax Expense$17.83M$7.20M$18.27M$16.63M$9.86M$11.62M$6.68M$16.08M$10.10M$13.45M$13.08M$13.37M
    Net Income$75.43M$32.49M$22.49M$50.87M$39.78M$45.56M$49.48M$46.09M$11.59M$38.33M$26.61M$38.46M
    EBITDA$94.96M$43.06M$44.29M$71.50M$53.66M$61.65M$61.53M$67.18M$27.00M$57.60M$45.85M$71.14M
    EBIT$89.26M$37.16M$38.45M$65.38M$47.99M$55.97M$55.89M$61.59M$21.39M$51.89M$40.39M$64.50M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about HRMY

    News

    Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

    Harmony Biosciences Holdings, Inc. announced its management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026, at 10:20 a.m. E.T. A webcast of the event will be available on the company's investor relations website. Harmony Biosciences is a pharmaceutical company focused on developing therapies for rare neurological diseases.

    Yahoo Finance•8/27/26•
    Somewhat-Bullish

    Wolfe Research initiates Harmony Biosciences stock at Outperform

    Wolfe Research has initiated coverage on Harmony Biosciences (NASDAQ:HRMY) with an Outperform rating and a $60 price target, citing significant upside potential and the resilience of its Wakix franchise. Despite ongoing IP litigation, Wakix is projected to reach $1 billion in sales in 2026, with new formulations expected to extend IP protection into the 2040s. The firm also anticipates future upside from BP-205, with important data readouts expected in late 2026 and early 2027.

    Investing.com•8/26/26•
    Bullish

    Tieton Capital Management LLC Takes Position in Harmony Biosciences Holdings, Inc. $HRMY

    Tieton Capital Management LLC has acquired a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) during the second quarter, purchasing 306,781 shares valued at approximately $11.17 million. This investment makes Harmony Biosciences the 16th largest holding in Tieton Capital Management LLC's portfolio, representing 3.2% of its total assets. Other institutional investors have also adjusted their stakes in Harmony Biosciences, and the company has received mixed analyst ratings with an average "Hold" rating and a price target of $45.50.

    MarketBeat•8/20/26•
    Somewhat-Bullish

    Denali Advisors LLC Purchases 29,700 Shares of Harmony Biosciences Holdings, Inc. $HRMY

    Denali Advisors LLC has significantly increased its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by purchasing an additional 29,700 shares, bringing its total holdings to 89,600 shares valued at approximately $3.26 million. This move comes as Harmony Biosciences reported strong quarterly earnings, surpassing analyst expectations with $1.28 EPS and $261.28 million in revenue. Despite a consensus "Hold" rating from analysts, the company's stock shows positive momentum, with institutional investors collectively owning a substantial 86.23% of the company.

    MarketBeat•8/20/26•
    Somewhat-Bullish

    Aurora Investment Counsel Invests $2.37 Million in Harmony Biosciences Holdings, Inc. $HRMY

    Aurora Investment Counsel has acquired a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), purchasing 65,148 shares valued at approximately $2.37 million, making it their 22nd largest holding. Other institutional investors have also adjusted their stakes in Harmony Biosciences. The company's stock recently increased by 2.8%, and analysts have issued various ratings, with the consensus being a "Hold" with a target price of $45.50.

    MarketBeat•8/20/26•
    Bullish

    Frequently Asked Questions About HRMY

    Does HRMY pay dividends?
    Harmony Biosciences Holdings (HRMY) does not currently pay a regular dividend.
    What is HRMY's P/E ratio?
    Harmony Biosciences Holdings has a price-to-earnings (P/E) ratio of 10.59.
    What is HRMY's market cap?
    Harmony Biosciences Holdings (HRMY) has a market capitalization of $2.29B with a current stock price of $39.38.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In